Author name: Graviton

Small Molecule FASN Inhibitors Demonstrate Antiviral Activity Menlo Park, California, November 10, 2012. 3–V Biosciences, Inc., announced today that preclinical […]

Menlo Park, California, October 1, 2012. 3­‐V Biosciences, Inc., announced today that two abstracts have been accepted for presentation at

Menlo Park, California, July 10, 2012. 3-­V Biosciences, Inc., announced today that George Kemble, PhD, Chief Scientific Officer, will present

Menlo Park, California, January 5, 2012. 3-V Biosciences, Inc. announced today both the closing of a Preferred Stock financing and the

Menlo Park, California, June 29, 2012. 3-V Biosciences, Inc., announced today the appointment of Douglas Buckley, PhD, as Vice President

Menlo Park, California, August 15, 2011. 3-V Biosciences, Inc. announced today the appointment of Dr. George W. Kemble, PhD as

Menlo Park, California, February 10, 2011. 3-V Biosciences, Inc. announced today Stephen R. Brady has been named as Chief Business

Menlo Park, California, September 30, 2010. 3-V Biosciences, Inc. announced today the appointment of Merdad V. Parsey, MD, PhD as

Menlo Park, California, July 20, 2010. 3-V Biosciences, Inc. today announced the appointment of James F. Young, Ph.D. to its